AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...